Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6)....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of microbiology, immunology and infection immunology and infection, 2017-08, Vol.50 (4), p.541-544
Hauptverfasser:	Takamatsu, Kazufumi, Marumo, Satoshi, Fukui, Motonari, Hata, Atsuko
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Aged Aged, 80 and over Aging Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral drugs Cyclopentanes - administration & dosage Cyclopentanes - adverse effects Drug-Related Side Effects and Adverse Reactions - epidemiology Female Geriatrics Gerontology Guanidines - administration & dosage Guanidines - adverse effects High-risk patient Humans Influenza, Human - drug therapy Male Neuraminidase inhibitor Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6). Results confirm intravenous peramivir's usefulness.
ISSN:	1684-1182 1995-9133
DOI:	10.1016/j.jmii.2016.11.006